Board approves Q1 FY27 results, auditor gives clean review
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Onesource Specialty Pharma board on July 24, 2026 approved unaudited standalone and consolidated financial results for Q1 FY27, quarter ended June 30, 2026. Auditor Deloitte Haskins and Sells issued an unmodified review report on both sets of results. Consolidated results cover 7 entities including 6 subsidiaries. Two subsidiaries reviewed by other auditors contributed about Rs 283.47 million in revenue and Rs 12.14 million net loss. Four unreviewed subsidiaries had nil revenue and Rs 1.79 million loss, deemed not material.
Clean auditor review, standard quarterly results approval. No red flags in the auditor report. Detailed financials not included in this filing.